Nesiritide
In clinical developmentAlso known as B-type natriuretic peptide, BNP, BNP-32, Brain natriuretic peptide+6 more
B-type natriuretic peptide, BNP, BNP-32, Brain natriuretic peptide, Brain natriuretic peptide 32, Human brain natriuretic factor-32, Natrecor, Natriuretic peptide B Type, Nesiritide (E. coli), nesiritide (hBNP).
Recent clinical, regulatory, research and industry developments relating to this drug.
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1
Therapeutic Effects of BNP in Hypertensive Patients
Septic cArdiac Deficiency and MenIngococcal seveRe Sepsis
BNP Pharmacodynamics and Effects on Metabolism in Lean and Obese Subjects
Natriuretic Peptides and Metabolic Risk in Obesity
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- Circulation. Heart failure1
- Journal of cardiac failure1
- Journal of the American College of Cardiology1
- Chew E2
- Chow SL2
- Heywood JT2
- O'Barr SA2
- Pak F2
- Patel P2
- Patterson JH2
- Peng J2
- College of Pharmacy2
- University of Florida1
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials